Pharmaceutical

(Curcumin + doxorubicin) by Immix BioPharma for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

Dec 24, 2023 - 18:00
(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC).
Read the original article

Tags:

Previous Article

Mecbotamab vedotin by BioAtla for Breast Cancer: Likelihood of Approval

Next Article

(Curcumin + doxorubicin) by Immix BioPharma for Metastatic Colorectal Cancer: Li...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

After decades of neglecting women athletes, sport and exercise medicine is finally catching up

After decades of neglecting women athletes, sport and e...

May 19, 2023

After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN

After failed FSGS bid, Travere wins full FDA approval f...

Sep 8, 2024

mRNA licensing agreements double with million-dollar deals

mRNA licensing agreements double with million-dollar deals

Oct 8, 2024